Delta4 is a TechBio company revolutionizing drug discovery with its proprietary AI platform, Hyper-C. This platform enables the identification of new indications for existing drugs with known safety profiles through advanced algorithms and big data analysis. Delta4 focuses on accelerating the development of novel therapies, enhancing patient health and access to effective treatments. The team comprises computational and molecular biologists, developers, and other experts dedicated to overcoming challenges in pharmaceutical development. With a structured 7-step process, the company streamlines operations for faster, cost-effective results. Delta4 is a proud member of Scientist.com, promoting transparency and collaboration in drug discovery.
• data integration
• big data analysis
• hyper-c ai platform
• drug indication expansion
• compliance with regulatory requirements
Average Rating: 0.0
5 Stars:
0 Ratings
4 Stars:
0 Ratings
3 Stars:
0 Ratings
2 Stars:
0 Ratings
1 Star:
0 Ratings
No ratings available.
AI platform for drug discovery using advanced data analytics and machine learning.
View DetailsAI-powered platform for drug discovery using novel therapeutics and machine learning.
View DetailsAI-powered small molecule drug discovery platform accelerating drug development.
View DetailsA federated AI framework that integrates decentralized data sources for AI development.
View Details